

Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles[☆]

Ramani R. Ranatunge,^{*,‡} David S. Garvey, David R. Janero, L. Gordon Letts, Allison M. Martino, Madhavi G. Murty, Stewart K. Richardson, Delano V. Young and Irina S. Zemetseva

NitroMed Inc., 12 Oak Park Drive, Bedford, MA 01730, USA


Received 20 November 2003; revised 13 January 2004; accepted 14 January 2004

Abstract—Novel series of pyrazolo[5,1-*b*]1,3-oxazolidines, pyrazolo[5,1-*b*]1,3-oxazines and imidazolidino[1,2-*d*]pyrazoles were synthesized. These compounds were evaluated *in vitro* for their ability to inhibit cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in human whole blood (HWB). Several of the compounds were found to be novel and selective COX-2 inhibitors, the most potent and selective being 1-(5-cyclohexyl (2H,3H-pyrazolo[5,1-*b*]-1,3-oxazolidin-6-yl)-4-(methylsulfonyl)benzene, **7a** (IC₅₀ for COX-1 > 100 μM; for COX-2 = 1.3 μM).


© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat acute or chronic inflammation and offer symptomatic pain relief.^{1,2} Conventional NSAIDs act by non selective inhibition of cyclooxygenase (COX) enzymes, which catalyze the formation of prostaglandins (PGs) from arachidonic acid.^{3–5} There are at least two main mammalian COX isoforms, COX-1 and COX-2.^{6,7} Constitutive COX-1 has housekeeping functions, including low-level production of gastroprotective PGs, whereas COX-2 is induced in inflammatory cells and generates PGs that help mediate the inflammatory response. Adverse gastrointestinal (GI) side-effects of conventional NSAIDs largely reflect inhibition of COX-1 and the associated reduction in gastroprotection.^{8–11} In contrast, selective COX-2 inhibitors such as Celecoxib,¹² Rofecoxib¹³ and Valdecoxib¹⁴ exert anti-inflammatory and analgesic activity in the clinic with markedly less GI toxicity than traditional NSAIDs.



The improved GI tolerance of COX-2 selective inhibitors notwithstanding, there is evidence to suggest that COX-2 selective inhibitors may inhibit COX-1 and induce GI irritation or ulceration with long-term use or at higher doses.^{15–18} Preclinical cardiovascular and renal liabilities of at least some COX-2 selective inhibitors have also been reported.¹⁹ Thus there is still a need for new, selective COX-2 inhibitors with an improved safety profile.



A search of the literature revealed very few reports of COX-2 selective inhibitors containing a bicyclic core.

[☆]A portion of this work was presented in a poster at the 225th ACS National Meeting, Medicinal Chemistry (abstr. #245), New Orleans, LA, USA, 23–27 March 2003.

^{*}Corresponding author. Tel.: +1-781-685-9739; fax: +1-781-275-1127; e-mail: rbandarage@nitro-med.com

[‡]Following the senior author, contributors appear in alphabetical order.

Two examples are the imidazo[1,2-*a*]-pyridines²⁰ and the pyrazolo[1,5-*b*]pyridazines²¹ which contain a planar central unit. A slightly less rigid system can be found in the 2,3-dihydro-1H-pyrrolines as exemplified by ML 3000.^{22–27} We now wish to report the synthesis and COX-2 selective inhibition of a series of novel bicyclic-pyrazole inhibitors. While this manuscript was in preparation, a patent²⁸ appeared covering this structural core, but the compounds reported herein have not been fully described or characterized.

2. Chemistry


The general routes outlined in Schemes 1–3 were used to synthesize all compounds described herein. The key synthetic step for construction of the bicyclic-pyrazole core involves either basic or acidic cyclization of 2-hydroxyalkyl pyrazole intermediates (**4**, **10**, **18**, **26**).

As shown in Scheme 1, pyrazolo[5,1-*b*]1,3-oxazolidines **7a–c** and pyrazolo[5,1-*b*]1,3-oxazine **12** were obtained from commercially available 2-(4-methylthiophenyl)-acetic acid, **1**. This was converted into the corresponding methyl ester **2**, whose enolate, prepared using LiHMDS, reacted with acid chlorides to give the ketoesters **3** in high yield. This was condensed with hydrazinoalkanoles²⁹ in glacial acetic acid at 100 °C to obtain 2-hydroxyalkyl substituted pyrazoles **4** and **10** in high yield. In most cases, 1,3,4-substituted pyrazoles (**4**, **10**) were formed exclusively. In those few cases where the 1,2,3-regioisomer was also formed as a minor by-product, it was readily removed by column chromatography followed by recrystallization. Bicyclic-pyrazoles **9** and **11** were obtained by bromination of **4** or **10** with CBr₄ and PPh₃ (or polymer supported PPh₃) followed by cyclization using K₂CO₃.

In fact, minor quantities of **9** or **11** were formed during the bromination of **4** or **10**, indicating that cyclization was spontaneous but slow in the absence of base. Methyl sulfides **9** and **11** were oxidized to the sulfones (**7a–c**, **12a**) with Oxone[®] in high yield. Alternatively, **7a–c** could be synthesized from **4** by reversing the order of oxidation and cyclization (**4** to **5** to **6** to **7**). In this route however, the oxidation of **4** gave a low isolated yield due to the high polarity and insolubility of **5**.

Imidazolidino[1,2-*d*]pyrazoles (**21**, **22**, **24**, **25**) were prepared as illustrated in Scheme 2. The ketonitrile intermediate **16** was prepared in three steps from commercially available 4-methylthiobenzyl alcohol **13**. Reaction of **13** with SOCl₂ gave **14** in 97% yield. Substitution of the chloride with NaCN gave the nitrile **15** which, upon acylation with cyclohexanecarbonyl chloride in the presence of LiHMDS, afforded ketonitrile **16**. This was condensed with 2-hydroxyethyl hydrazine in glacial acetic acid at 100 °C to give 5-amino-1-(2-hydroxyethyl)pyrazole **17**. Mesylation of **17** afforded **18**, which was cyclized in the presence of K₂CO₃ at 60 °C for 3 days to give imidazolidino[1,2-*d*]pyrazole **19**. Oxidation of the sulfide group of **19** with Oxone[®] at room temperature gave a significant amount of *N*-oxide as a by-product together with the desired product **20**. When the reaction was repeated at 0 °C, *N*-oxide formation was greatly reduced. Acylation of **20** with acetic anhydride gave 4-acetyl-imidazolidino[1,2-*d*]pyrazole **21**. On the other hand, alkylation of **20** with methyl iodide and K₂CO₃ in DMF at room temperature gave *N*-methyl-imidazolidino [1,2-*d*]pyrazole **22**.

Incorporating an acid group into the molecule could be useful either to improve its solubility or to allow for further chemical modification. Therefore, imidazolidino[1,2-*d*]-



Scheme 1. (a) MeOH, c. H₂SO₄, rfx, 16 h; (b) LiHMDS, RCOCl, THF; (c) gl. acetic acid, NH₂NH(CH₂)₂OH, 100 °C, 1 h; (d) gl. acetic acid, NH₂NH(CH₂)₃OH, 100 °C, 1 h; (e) polymer supported-PPh₃, CBr₄, DMF, rt, 3 days or CBr₄, PPh₃, CH₂Cl₂, rt, 3 days; (f) K₂CO₃/DMF, rt, 1 h; (g) Oxone, MeOH/H₂O, rt.

pyrazolyl-2-acetic acid **25** (Scheme 2) was targeted. Compound **19** was alkylated with *tert*-butylbromoacetate in the presence of K_2CO_3 to give **23**, which was oxidized with Oxone[®] at 0 °C to give the sulfone **24**. Cleavage of the *tert*-butyl ester group in **24** afforded imidazolidino[1,2-*d*]pyrazolyl-2-acetic acid **25**.

In order to incorporate a *gem* dimethyl group, as found in ML 3000, compound **28** was targeted and prepared as shown in Scheme 3. Ketoester **3a** was condensed with 1-hydrazino-2-methyl-2-propanol³⁰ in glacial acetic acid at 100 °C for 1 h to give the pyrazolediol **26**. This was subjected to cyclization under acidic conditions to provide the methyl sulfide **27** along with unreacted **26**. Oxidation of methyl sulfide **27** with Oxone[®] gave the pyrazolo[5,1-*b*]1,3-oxazolidine **28**.


3. Results and discussion

The compounds were tested for their ability to inhibit COX-1 and COX-2 isozymes in human whole blood (HWB).^{31–32} For this initial in vitro screen, compounds


were assayed against COX-1 at 100 μ M and COX-2 at 10 μ M and 1 μ M (Table 1). For the most potent and selective COX-2 inhibitors, full IC_{50} 's were then determined (Table 2).

The results reported in Table 1 show that the substituent at the position 5 of the pyrazolo[5,1-*b*]oxazolidine is critically important. Having a cyclohexyl group, **7a** showed selective COX-2 inhibition (COX-2 inhibition: 90% at 10 μ M and 25% at 1 μ M; COX-1 inhibition: 25% at 100 μ M). Replacement of the cyclohexyl group at position 5 of **7a** by a phenyl group enhanced COX-1 inhibitory activity slightly (COX-1 inhibition by **7b**: 40% at 100 μ M) while leaving COX-2 activity unaffected. Surprisingly, substitution of a benzyl group at position 5, as in **7c**, resulted in complete loss of COX-1 and COX-2 activity. The COX inhibitory IC_{50} 's for **7a** (COX-1 > 100 μ M; COX-2 1.3 μ M) confirmed the conclusion that **7a** is a highly potent and selective COX-2 inhibitor (Table 2).


On the basis of the COX-2 potency and selectivity demonstrated by pyrazolo[5,1-*b*]oxazolidine **7a**, this was



Scheme 2. (a) $SOCl_2$, toluene, rt, 30 min, 97%; (b) NaCN, DMSO, rt, 2 h, 89%; (c) cyclohexanecarbonyl chloride, LiHMDS, THF, $-78^\circ C$ to rt, 67%; (d) gl. acetic acid, $NH_2NH(CH_2)_2OH$, 100 °C, 1 h, 64%; (e) MsCl, Et_3N , CH_2Cl_2 , 0 °C, 10 min, 64%; (f) K_2CO_3 , DMF, 60 °C, 3 days, 44%; (g) Oxone, MeOH, H_2O , 0 °C, 2 h; (h) MeI, K_2CO_3 , rt, 7 days, 39%; (i) Ac_2O , DMAP, CH_2Cl_2 , rt, 16 h, 36%; (j) *tert*-Butylbromoacetate, K_2CO_3 , DMF, rt, 5d, 80%; (k) TFA, CH_2Cl_2 , rt, 3 h, 69%.



Scheme 3. (a) gl. acetic acid, $NH_2NHCH_2C(CH_3)_2OH$, 100 °C, 1 h; (b) neat phosphoric acid, 70 °C, 6 h; (c) Oxone, MeOH/ H_2O , rt, 2 h.

Table 1. In vitro human whole blood COX-1 and COX-2 inhibition by bicyclic-pyrazole derivatives

Compd	R	R ₁	% Inhibition HWB ^a		
			COX-1	COX-2	
			100 μM	10 μM	1 μM
7a	Cyclohexyl		25	90	25
7b	Phenyl		40	90	20
7c	Benzyl		0	0	0
12a	Cyclohexyl		35	25	10
20		-H	65	80	5
21		-COCH ₃	20	10	0
22		-CH ₃	0	38	0
24		-CH ₂ COO ^t Bu	50	55	55
25		-CH ₂ COOH	48	34	0
28			0	12.5	0
	Celecoxib		65 ^b	100	50
	Rofecoxib		75	100	75

^a Percent inhibition of COX-1 (100 μM) or COX-2 (10 and 1 μM) in human whole blood. Assays were performed in duplicate. Average % inhibition using blood from two donors (see Experimental).

^b COX-inhibition at 30 μM Celecoxib.

selected for further modification (Table 1). Changing the bicyclic ring from five- to six-membered (to give pyrazolo[5,1-*b*]oxazine **12**) significantly compromised COX-2 potency (COX-2 inhibition: 25% at 10 μM and 10% at 1 μM). This loss of COX-2 inhibitory potency suggests that, in this series, a fused six-membered bicyclic ring is detrimental to COX-2 activity.

We next investigated substituting the oxygen in compound **7a** with a nitrogen atom. To this end, a series of imidazolidino[1,2-*d*]pyrazoles was synthesized (Scheme 2) and evaluated for COX inhibition (Table 1). Compound **20** showed good potency toward COX-2 at 10 μM, although with reduced COX-2 selectivity in comparison to **7a** (COX-2 inhibition by **20**: 80% at 10 μM

and 5% at 1 μM; COX-1 inhibition: 65% at 100 μM). Additional substitution at the available nitrogen of **20**, specifically *N*-acylation (to give **21**) and *N*-methylation (to give **22**), reduced all COX inhibitory activity. Compound **24**, containing a bulky and hydrophobic *tert*-butyl ester, showed good, but seemingly concentration independent, COX-2 activity (COX-2 inhibition: 55% at both 10 μM and 1 μM) and moderate selectivity versus COX-1 (COX-1 inhibition: 50% at 100 μM) in comparison to **7a**. The acid **25** was found to be a less potent COX-2 inhibitor than **24**. In view of the greater activity of **24** over **25**, other ester and amide derivatives could be envisioned as rational attempts to enhance COX-2 inhibitor potency and selectivity. Finally, we explored the effect of substitution on the saturated ring of **7a**, since the potent and selective COX-2 inhibitor ML 3000 has a bicyclic ring system substituted with two methyl groups. Compound **28**, which appeared to mimic this feature, had however, almost zero activity indicating that other features of ML 3000 are important contributors to enzyme binding.

4. Conclusion

Activation of a hydroxyalkyl group attached to the pyrazole nucleus followed by cyclization produced three new series of bicyclic-pyrazoles. Several compounds

Table 2. IC₅₀ Values of bicyclic-pyrazole, **7a** and some standard COX-2 inhibitors in human blood

Compd	IC ₅₀ (μM)	
	COX-1	COX-2
Celecoxib	14	1.2
Rofecoxib	40	0.3
ML3000 ²¹		0.21 ^a
7a	> 100	1.3

^a IC₅₀ value for inhibition of cyclooxygenases.²³

were found to be selective COX-2 inhibitors, the most potent and selective being the pyrazolo[5,1-*b*]1,3-oxazolidine **7a** (IC₅₀'s for COX-1 > 100 μM; COX-2 1.3 μM). Although marginally less potent than celecoxib and rofecoxib (Table 1), identification of **7a** as a lead compound from such a small series of compounds is encouraging. Modification of **7a** may generate still more potent and selective inhibitors.

5. Experimental

5.1. COX-Inhibition—HWB assay

Fresh human blood, obtained by informed consent from non-fasted donors of either sex who had not taken aspirin or any NSAID during the prior 14 days, was collected in sodium heparin (20 units/mL) and distributed in 1 mL aliquots per well of 24-well tissue culture plate. The plates were placed on a gently rotating platform shaker in a 5% CO₂ incubator at 37°C for 15 min. Test compounds were dissolved and diluted in DMSO, and 1 μL of each dilution of the test compound was added per well in duplicate wells. To induce COX-2, lipopolysaccharide from *E. coli* (Sigma Chemical Co., St. Louis, MO) was added at 10 μg/mL to appropriate wells 15 min after the addition of the test compounds. To activate COX-1, the calcium ionophore A23187 (Sigma Chemical Co., St. Louis, MO) was added to a final concentration of 25 μM to separate wells 4.75 h after the addition of the test compounds. At 30 min after A23187 addition or 5 h after LPS addition, all incubations were terminated. The blood samples were processed for thromboxane B₂ determination and assayed in duplicate by EIA (Cayman Chemical Co., Ann Arbor, MI).³¹ COX inhibition data in the text and tables are derived from averages of two EIA determinations on each of duplicate blood sample from two donors.

5.2. General procedures

All reagents and anhydrous solvents were generally used as received from the commercial supplier. Reactions were routinely performed under a nitrogen atmosphere in oven-dried glassware. Melting points were determined with an electrothermal heating block (Mettler) and are uncorrected. ¹H and ¹³C NMR spectra were recorded at 300 and 75 MHz, respectively. NMR spectra were recorded in CDCl₃ unless otherwise specified, and chemical shifts are reported relative to tetramethylsilane as an internal standard. Low-resolution mass spectra were obtained using atmospheric pressure-turbo ion spray ionization. Elemental analyses were performed by Robertson Microlit Laboratories Inc., Madison, NJ. Gravity and flash column chromatography were performed using EM Science silica gel 60 (230–400 mesh). Analytical TLC was performed on 250 μM pre-coated EM Science silica gel 60 F₂₅₄ aluminum sheets. Preparative TLC was performed using 20×20 cm 1000 μM pre-coated silica gel plates (Whatman). Spots were visualized under 254 nm light or after staining with phosphomolybdate spray.

5.3. 1-(5-Cyclohexyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl)-4-(methylsulfonyl) benzene (**7a**)

5.3.1. Methyl 2-(4-methylthiophenyl)acetate (2**).** Concentrated sulfuric acid (1 mL) was added dropwise to a solution of 2-(4-methylthiophenyl)acetic acid **1** (5.0 g, 27.4 mmol) in MeOH (40 mL) at room temperature. The resultant mixture was heated at 50°C for 16 h, cooled to room temperature and the solvent was evaporated. The residue was dissolved in EtOAc, washed with saturated NaHCO₃, dried over Na₂SO₄ and filtered. The filtrate was evaporated to give **2** (5.4 g, ~100%) as a viscous oil. ¹H NMR δ 7.18–7.26 (m, 4H), 3.69 (s, 3H), 3.58 (s, 2H), 2.47 (s, 3H). ¹³C NMR δ 172.0, 137.4, 130.9, 129.8, 127.0, 52.1, 40.7, 16.0. MS *m/z* 197 (MH⁺), 214 (MNH₄⁺), 219 (MNa⁺), 137 (M-COOCH₃). Anal. calcd (C₁₀H₁₂O₂S): C, 61.20; H, 6.16. Found: C, 60.79; H, 5.80.

5.3.2. Methyl 3-cyclohexyl-2-(4-methylthiophenyl)-3-oxopropanoate (3a**).** To a stirred solution of **2** (4.9 g, 25.0 mmol) in THF (50 mL) was added dropwise a solution of lithium bis(trimethylsilyl)amide (1 M solution in THF, 62.4 mL, 62.4 mmol) at –78°C under nitrogen. The resulting solution was stirred at –78°C for 10 min and then at room temperature for 1 h. The reaction mixture was cooled to –78°C and cyclohexanecarbonyl chloride (5.49 g, 37.4 mmol) was added dropwise. The mixture was allowed to warm to 0°C over 1 h and then stirred at 0°C for 1 h. Saturated NH₄Cl was added and the organic layer was separated. The aqueous phase was extracted with EtOAc and the combined organic phases were washed with brine and dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:9 EtOAc:Hex to give **3a** (7.6 g, 99%) as a white crystalline solid. Mp 104–106°C. ¹H NMR δ 13.12 (s, 1H), 7.20–7.26 (m, 2H), 7.03–7.09 (m, 2H), 3.68 (s, 3H), 2.52 (s, 3H), 2.10–2.16 (m, 1H), 1.55–1.72 (m, 7H), 1.02–1.20 (m, 3H). ¹³C NMR δ 180.8, 173.5, 137.2, 131.8, 131.7, 126.2, 101.9, 51.9, 41.2, 29.5, 25.7, 15.7. MS *m/z* 307 (MH⁺), 324 (MNH₄⁺). Anal. calcd (C₁₇H₂₂O₃S): C, 66.64; H, 7.24; N, 10.46. Found: C, 66.61; H, 7.34; N, 10.39.

5.3.3. 3-Cyclohexyl-1-(2-hydroxyethyl)-4-(4-methylthiophenyl)pyrazol-5-ol (4a**).** A mixture of **3a** (5.52 g, 18.0 mmol) and 2-hydroxyethylhydrazine (6.17 g, 81.2 mmol) in glacial AcOH (24 mL) was heated at 100°C for 1 h. The solvent was evaporated and dried under vacuum to give a pale yellow solid which was dissolved in 1:9 MeOH:CH₂Cl₂. To this solution, water was added and the resultant precipitate was filtered, washed with water and then hexane to give **4a** (2.75 g, 46%) as an off-white solid. Mp 204–205°C. ¹H NMR (*d*₄-MeOH) δ 7.26–7.32 (m, 4H), 3.98 (t, *J* = 5.7 Hz, 2H), 3.80 (t, *J* = 5.6 Hz, 2H), 2.76–2.84 (m, 1H), 2.47 (s, 3H), 1.22–1.87 (m, 10H). ¹³C NMR (*d*₄-MeOH) δ 152.8, 138.0, 130.8, 130.3, 127.7, 105.4, 60.9, 47.6, 37.1, 32.9, 27.4, 26.9, 15.9. MS *m/z* 333 (MH⁺). Anal. calcd (C₁₈H₂₄N₂O₂S): C, 65.03; H, 7.28; N, 8.43; S, 9.64. Found: C, 64.80; H, 7.30; N, 8.30; S, 9.53.

5.3.4. 1-[3-Cyclohexyl-5-hydroxy-1-(2-hydroxyethyl)pyrazol-4-yl]-4-(methylsulfonyl) benzene (5a). To a solution of **4a** (316 mg, 0.95 mmol) in MeOH (18 mL) was added dropwise a solution of Oxone[®] (1.35 g, 2.20 mmol) in water (4 mL). The white suspension was stirred at room temperature for 30 min. The solid was filtered and washed with CH₂Cl₂. The filtrate was treated with water to give a white precipitate. The precipitate was filtered and washed with water and hexane to give **5a** (0.15 g, 43%) as a white solid. Mp 247–249 °C. ¹H NMR (*d*₄-MeOH) δ 7.96 (d, *J* = 8.1 Hz, 2H), 7.69 (d, *J* = 8.2 Hz, 2H), 4.02 (t, *J* = 5.6 Hz, 2H), 3.81 (t, *J* = 5.6 Hz, 2H), 3.13 (s, 3H), 2.84–2.96 (m, 1H), 1.20–1.95 (m, 10H). ¹³C NMR (CDCl₃/*d*₄-MeOH) δ 152.7, 139.8, 138.7, 130.2, 128.3, 103.6, 60.7, 47.5, 44.6, 36.8, 32.7, 27.2, 26.6. MS *m/z* 365 (MH⁺). Anal. calcd (C₁₈H₂₄N₂O₄S·1/2 mol H₂O): C, 57.89; H, 6.74; N, 7.50; S, 8.58. Found: C, 58.18; H, 6.54; N, 7.40; S, 8.40.

5.3.5. 1-[1-(2-bromoethyl)-3-cyclohexyl-5-hydroxypyrazol-4-yl]-4-(methylsulfonyl)benzene (6a). To a stirred solution of **5a** (140 mg, 0.38 mmol) and carbon tetrabromide (191 mg, 0.57 mmol) in CH₂Cl₂ (0.8 mL) at 0 °C under nitrogen was added a solution of triphenylphosphine (151 mg, 0.57 mmol) in CH₂Cl₂ (0.4 mL). The resultant orange solution was stirred at room temperature for 3 days. The residue after evaporation of the solvent was chromatographed on silica gel eluted with 0.5:9.5 MeOH: CH₂Cl₂ to give **6a** (152 mg, 93%) as a pale yellow foam. ¹H NMR δ 7.90 (d, *J* = 8.2 Hz, 2H), 7.63 (d, *J* = 8.3 Hz, 2H), 4.22 (t, *J* = 6.0 Hz, 2H), 3.66 (t, *J* = 5.9 Hz, 2H), 3.07 (s, 3H), 2.78–2.82 (m, 1H), 1.20–1.92 (m, 10H). MS *m/z* 427 / 429 (MH⁺).

5.3.6. 1-(5-Cyclohexyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl)-4-(methylsulfonyl) benzene (7a). To a solution of **6a** (0.15 g, 0.35 mmol) in DMF (9 mL), K₂CO₃ (58 mg, 0.45 mmol) was added. The resultant mixture was stirred at room temperature for 3 h. The solid was filtered and the solvent was evaporated. The residue was extracted with EtOAc and the organic phase was washed with water, brine and then dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:1 EtOAc:CH₂Cl₂ to give **7a** (75 mg, 62%) as a white solid. Mp 172–173 °C. ¹H NMR δ 7.94 (d, *J* = 8.5 Hz, 2H), 7.61 (d, *J* = 8.4 Hz, 2H), 5.15 (t, *J* = 7.7 Hz, 2H), 4.36 (t, *J* = 8.3 Hz, 2H), 3.10 (s, 3H), 2.80–2.92 (m, 1H), 1.25–2.05 (m, 10H). ¹³C NMR δ 160.9, 157.4, 138.7, 136.7, 127.9, 127.2, 94.0, 75.7, 45.5, 44.8, 38.2, 32.7, 26.8, 26.2. MS *m/z* 347 (MH⁺). Anal. calcd (C₁₈H₂₂N₂O₃S): C, 62.40; H, 6.40; N, 8.09. Found: C, 62.32; H, 6.30; N, 8.02.

5.4. 4-(Methylsulfonyl)-1-(5-phenyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl))benzene (7b)

5.4.1. Methyl 2-(4-methylthiophenyl)-3-oxo-3-phenylpropanoate (3b). To a stirred solution of **2** (6.0 g, 36.0 mmol) in THF (60 mL) was added dropwise a solution of lithium bis(trimethylsilyl)amide (1M solution in THF, 76.5 mL, 76.5 mmol) at –78 °C under nitrogen. The resulting solution was stirred at –78 °C for 10 min

and then at room temperature for 1 h. The reaction mixture was cooled to –78 °C, and benzoyl chloride (6.45 g, 45.9 mmol) was added dropwise. The mixture was allowed to warm to room temperature over 1 h and stirred at room temperature for 16 h. The mixture was cooled to 0 °C. To this solution, saturated NH₄Cl was added, and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic phases were washed with brine and dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was recrystallized from CH₂Cl₂/Hex to give **3b** (7.97 g, 87%) as a pale yellow solid. Mp 82–83 °C. ¹H NMR δ 7.88–7.95 (m, 2H), 7.77–7.82 (m, 1H), 7.18–7.54 (m, 6H), 5.56 (s, 1H), 3.73 (s, 3H), 2.42 (s, 3H). MS *m/z* 301 (MH⁺), 318 (MNH₄⁺).

5.4.2. 1-(2-Hydroxyethyl)-4-(4-methylthiophenyl)-3-phenylpyrazol-5-ol (4b). A mixture of **3b** (3.5 g, 11.7 mmol) and 2-hydroxyethylhydrazine (3.99 g, 52.4 mmol) in glacial AcOH (35 mL) was heated at 100 °C for 1 h. The solvent was evaporated to give a pale yellow oil which was dissolved in EtOAc. To this solution, water was added, the resultant precipitate was filtered and washed with water, hexane and then dried under vacuum to give **4b** (2.36 g, 62%) as a white solid. Mp 235–237 °C. ¹H NMR (DMSO-*d*₆) δ 7.14–7.36 (m, 9H), 4.02 (t, *J* = 6.2 Hz, 2H), 3.76 (t, *J* = 6.3 Hz, 2H), 2.46 (s, 3H). ¹³C NMR (DMSO-*d*₆) δ 145.7, 135.1, 129.7, 129.5, 128.2, 127.6, 125.9, 101.5, 59.5, 48.4, 14.8. MS *m/z* 327 (MH⁺), 349 (MNa⁺). Anal. calcd (C₁₈H₁₈N₂O₂S): C, 66.23; H, 5.56; N, 8.58; S, 9.82. Found: C, 66.03; H, 5.57; N, 8.47; S, 9.82.

5.4.3. 1-(2-Bromoethyl)-4-(4-methylthiophenyl)-3-phenylpyrazol-5-ol (8b). To a stirred solution of **4b** (0.81 g, 2.48 mmol) in DMF (16 mL) was added polymer supported triphenylphosphine (1.65 g of resin, 3 mmol of P/g of resin, 5 mmol). The mixture was stirred at room temperature for 30 min under nitrogen. To this mixture, carbon tetrabromide (1 g, 2.98 mmol) was added portionwise. The resultant mixture was stirred at room temperature for 4 days. The solid was filtered and washed with EtOAc. The residue after evaporation of the solvent was dissolved in EtOAc/MeOH, washed with water, brine and then dried over Na₂SO₄. Filtration and evaporation of the solvent gave **8b** (0.76 g, 78%) as a pale yellow foam. ¹H NMR δ 7.15–7.42 (m, 9H), 4.34 (t, *J* = 6.5 Hz, 2H), 3.67 (t, *J* = 7.1 Hz, 2H), 2.47 (s, 3H). MS *m/z* 390 / 392 (MH⁺).

5.4.4. 4-Methylthio-1-(5-phenyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl))benzene (9b). Compound **9b** was synthesized in a manner similar to the synthesis of **7a** using **8b** (0.47 g, 1.21 mmol) and K₂CO₃ (0.22 g, 1.56 mmol) in DMF (30 mL) to give **9b** (0.2 g, 54%) as a white foam. ¹H NMR δ 7.50–7.56 (m, 2H), 7.32–7.38 (m, 3H), 7.15–7.25 (m, 4H), 5.12 (t, *J* = 7.7 Hz, 2H), 4.40 (t, *J* = 8.3 Hz, 2H), 2.47 (s, 3H). ¹³C NMR δ 157.1, 154.5, 135.6, 134.5, 128.8, 128.5, 128.4, 128.1, 127.0, 95.4, 75.4, 45.6, 16.2. MS *m/z* 309 (MH⁺).

5.4.5. 4-(Methylsulfonyl)-1-(5-phenyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl))benzene (7b). To a solution of **9b**

(0.22 g, 0.71 mmol) in MeOH (9 mL) was added dropwise a solution of Oxone[®] (0.88 g, 1.43 mmol) in water (3 mL). The white suspension was stirred at room temperature for 1 h. The solid was filtered and washed with CH₂Cl₂. The filtrate was diluted with CH₂Cl₂, and the layers were separated. The organic phase was washed with water and then dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was recrystallized from CH₂Cl₂/EtOAc/Hex to give **7b** (0.23 g, 95%) as a white crystalline solid. Mp 194–195 °C. ¹H NMR δ 7.79 (d, *J* = 8.5 Hz, 2H), 7.35–7.52 (m, 7H), 5.20 (t, *J* = 7.8 Hz, 2H), 4.44 (t, *J* = 7.8 Hz, 2H), 3.04 (s, 3H). ¹³C NMR δ 157.7, 154.9, 138.0, 137.0, 134.0, 128.8, 128.6, 127.8, 127.6, 94.6, 75.9, 45.6, 44.7. MS *m/z* 341 (MH⁺). Anal. calcd (C₁₈H₁₆N₂O₃S): C, 63.51; H, 4.74; N, 8.23; S, 9.42. Found: C, 63.26; H, 4.70; N, 8.14; S, 9.32.

5.5. 4-(Methylsulfonyl)-1-(5-benzyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl))benzene (**7c**)

5.5.1. Methyl 2-(4-methylthiophenyl)-3-oxo-4-phenylbutanoate (3c**).** Compound **3c** was synthesized in a manner similar to the synthesis of **3b** using **2** (8.39 g, 42.8 mmol), phenyl acetyl chloride (9.9 g, 64.2 mmol) and lithium bis(trimethylsilyl)amide (1 M solution in THF, 107 mL, 107 mmol) in THF (60 mL). The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:9 EtOAc:Hex to give a mixture of ketoenol tautomers, **3c** (10 g, 75%) as a colorless oil. MS *m/z* 315 (MH⁺), 332 (MNH₄⁺).

5.5.2. 1-(2-Hydroxyethyl)-4-(4-methylthiophenyl)-3-benzylpyrazol-5-ol (4c**).** A mixture of **3c** (4.89 g, 15.6 mmol) and 2-hydroxyethylhydrazine (5.33 g, 70.0 mmol) in glacial AcOH (35 mL) was heated at 100 °C for 1 h. The residue after evaporation of the solvent was chromatographed on silica gel eluting with 0.2:9.8 to 0.5:9.5 MeOH:CH₂Cl₂ to give **4c** (2 g, 38%) as a pale yellow solid. Mp 121–123 °C. ¹H NMR δ 7.00–7.26 (m, 9H), 3.75–3.85 (m, 4H), 3.60–3.75 (m, 2H), 2.41 (s, 3H). ¹³C NMR δ 160.3, 145.5, 137.2, 136.5, 129.1, 128.8, 128.5, 128.5, 126.9, 126.7, 105.9, 61.0, 47.3, 32.1, 15.9. MS *m/z* 341 (MH⁺). Anal. calcd (C₁₉H₂₀N₂O₂S·1/2 mol H₂O): C, 65.30; H, 6.05; N, 8.02. Found: C, 65.33; H, 5.88; N, 8.13.

5.5.3. 1-(2-Bromoethyl)-4-(4-methylthiophenyl)-3-benzylpyrazol-5-ol (8c**).** Compound **8c** was synthesized in a manner similar to the synthesis of **6a** using **4c** (1 g, 2.94 mmol), carbon tetrabromide (1.17 g, 3.53 mmol) and triphenylphosphine (0.93 g, 3.53 mmol) in CH₂Cl₂ to give **8c** (1.08 g, 91%) as a pale yellow foam. ¹H NMR δ 7.13–7.30 (m, 9H), 4.25 (bt, *J* = 6.4 Hz, 2H), 3.95 (s, 2H), 3.65 (bs, 1H), 3.62 (bt, *J* = 6.4 Hz, 2H), 2.47 (s, 3H). MS *m/z* 403/405 (MH⁺).

5.6. 4-Methylthio-1-(5-benzyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl))benzene (**9c**)

The compound **9c** was synthesized in a manner similar to the synthesis of **7a** using **8c** (1.1 g, 2.7 mmol) and K₂CO₃ (0.49 g, 3.53 mmol) in DMF (10 mL). The residue

after evaporation of the solvent was chromatographed on silica gel eluted with 1:1:2 EtOAc:Hex:CH₂Cl₂ to give **9c** (0.34 g) contaminated with triphenylphosphine as a white foam which was used for the next step without further purification. MS *m/z* 323 (MH⁺).

5.6.1. 4-(Methylsulfonyl)-1-(5-benzyl(2H,3H-pyrazolo[5,1-*b*]1,3-oxazolidin-6-yl))benzene (7c**).** Compound **7c** was synthesized in a manner similar to the synthesis of **7b** using **9c** (0.34 g, 1.06 mmol) in MeOH (13 mL) and Oxone[®] (1.29 g, 2.1 mmol) in water (4 mL). The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:1:2 EtOAc:Hex:CH₂Cl₂ to give **7c** (70 mg, 19%) as a white solid. Mp 169–170 °C. ¹H NMR δ 7.81 (d, *J* = 8.6 Hz, 2H), 7.52 (d, *J* = 8.6 Hz, 2H), 7.19–7.30 (m, 5H), 5.17 (t, *J* = 7.8 Hz, 2H), 4.38 (t, *J* = 7.7 Hz, 2H), 4.15 (s, 2H), 3.01 (s, 3H). ¹³C NMR δ 157.7, 154.0, 138.7, 138.0, 136.6, 128.7, 128.5, 127.8, 126.8, 126.6, 95.2, 75.8, 45.5, 44.7, 35.6. MS *m/z* 355 (MH⁺). Anal. calcd (C₁₉H₁₈N₂O₃S): C, 64.39; H, 5.12; N, 7.90; S, 9.05. Found: C, 64.41; H, 5.07; N, 7.84; S, 8.99.

5.7. 1-(2-Cyclohexyl(5H,6H,7H-pyrazolo[5,1-*b*]1,3-oxazaperhydroin-3-yl))-4-(methylsulfonyl)benzene, (**12a**)

5.7.1. 3-Cyclohexyl-1-(3-hydroxypropyl)-4-(4-methylthiophenyl)pyrazol-5-ol (10**).** A mixture of **3a** (1.4 g, 4.6 mmol) and 3-hydroxypropylhydrazine²⁹ (1.85 g, 20.6 mmol) in glacial AcOH (10 mL) was heated at 100 °C for 1 h. The resultant solution was cooled to room temperature, neutralized with saturated NaHCO₃ and extracted with 9:1 CH₂Cl₂/MeOH. The combined extracts were dried over Na₂SO₄, filtered and evaporated. The residue was chromatographed on silica gel eluted with MeOH:CH₂Cl₂ to give **10** (0.85 g, 52%) as an oil. ¹H NMR (DMSO-*d*₆) δ 7.20–7.50 (m, 4H), 3.90–4.10 (m, 2H), 3.40–3.70 (m, 2H), 2.80–3.00 (m, 1H), 2.45 (s, 3H), 1.20–2.20 (m, 12H). MS *m/z* 361 (MH⁺).

5.7.2. 1-(2-Cyclohexyl(5H,6H,7H-pyrazolo[5,1-*b*]1,3-oxazaperhydroin-3-yl))-4-methylthiobenzene, (11**).** To a stirred solution of **10** (0.8 g, 2.3 mmol) in DMF (20 mL) was added polymer supported triphenylphosphine (1.54 g of resin, 3 mmol of P/g of resin, 4.6 mmol). The mixture was stirred at room temperature for 30 min under nitrogen. To this mixture, carbon tetrabromide (0.92 g, 2.8 mmol) was added portionwise. The resultant mixture was stirred at room temperature for 5 days. The solid was filtered and washed with EtOAc. The residue after evaporation of the solvent was diluted with 9:1 CHCl₃:MeOH washed with water, brine and then dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 9:1 CH₂Cl₂:MeOH to give **11** (0.4 g, 53%). ¹H NMR δ 7.19–7.42 (m, 4H), 3.80–4.02 (m, 4H), 2.72–2.85 (m, 1H), 2.52–2.69 (m, 2H), 2.41 (s, 3H), 1.20–2.05 (m, 10H). MS *m/z* 329 (MH⁺).

5.7.3. 1-(2-Cyclohexyl(5H,6H,7H-pyrazolo[5,1-*b*]1,3-oxazaperhydroin-3-yl))-4-(methylsulfonyl)benzene, (12a**).** Compound **12a** was synthesized in a manner similar to the synthesis of **7b** using **11** (50 mg, 0.15 mmol) in

MeOH (2 mL) and Oxone[®] (0.19 g, 0.3 mmol) in water (1 mL). The residue after workup was chromatographed on silica gel eluted with 1:9 MeOH:CH₂Cl₂ to give **12a** (30 mg, 55%) as a white solid. Mp 145–148 °C. ¹H NMR δ 7.97 (d, *J*=8.5 Hz, 2H), 7.66 (d, *J*=8.4 Hz, 2H), 3.80–4.05 (m, 4H), 3.10 (s, 3H), 2.75–2.93 (m, 1H), 2.60–2.75 (m, 2H); 1.20–2.05 (m, 10H). ¹³C NMR δ 159.8, 148.9, 138.8, 137.4, 129.6, 127.4, 108.4, 46.7, 44.6, 40.6, 36.2, 31.1, 27.4, 26.2, 25.7. MS *m/z* 361 (MH⁺). Anal. calcd (C₁₉H₂₄N₂O₃S·1/4 mol H₂O): C, 62.52; H, 6.77; N, 7.67. Found: C, 62.27; H, 6.76; N, 7.57.

5.8. 1-(2-Cyclohexylimidazolidino[1,2-*d*]pyrazol-3-yl)-4-(methylsulfonyl)benzene (**20**)

5.8.1. 1-(Chloromethyl)-4-methylthiobenzene (14**).** To a solution of 4-methylthiobenzyl alcohol **13** (8.5 g, 55.1 mmol) in toluene (85 mL) was added dropwise neat thionyl chloride (4.82 mL, 7.87 g, 66.1 mmol) at room temperature. The resultant pale yellow solution was stirred at room temperature for 30 min, and brine was added. The organic phase was separated, washed with brine, dried over Na₂SO₄ and filtered. The solvent was evaporated to give **14** (9.2 g, 97%) as a viscous oil. ¹H NMR δ 7.20–7.35 (m, 4H), 4.56 (s, 2H), 2.49 (s, 3H). ¹³C NMR δ 139.3, 134.3, 129.2, 126.7, 46.1, 15.8.

5.8.2. 2-(4-Methylthiophenyl)ethanenitrile (15**).** To a stirred suspension of sodium cyanide (3.15 g, 64.2 mmol) in DMSO (15 mL) was added dropwise a solution of **14** (9.2 g, 53.4 mmol) in DMSO (5 mL). The resultant mixture was stirred at room temperature for 2 h to give a pale yellow solution. Saturated NaCl was added, and the crude reaction mixture was extracted with EtOAc. The combined organic phases were washed with saturated NaCl, dried over Na₂SO₄ and filtered. The solvent was evaporated to give **15** (7.74 g, 89%) as a pale yellow solid. Mp 35–36 °C. ¹H NMR δ 7.20–7.30 (m, 4H), 3.69 (s, 2H), 2.47 (s, 3H). ¹³C NMR δ 138.8, 128.4, 127.1, 126.6, 117.9, 23.2, 15.8.

5.8.3. 3-Cyclohexyl-2-(4-methylthiophenyl)-3-oxopropanenitrile (16**).** To a stirred solution of **15** (4.0 g, 24.5 mmol) in THF (95 mL) was added dropwise a solution of lithium bis(trimethylsilyl)amide (1M solution in THF, 61.3 mL, 61.3 mmol) at –78 °C under nitrogen. The resulting solution was stirred at –78 °C for 10 min and then at room temperature for 1 h. The reaction mixture was cooled to –78 °C, and cyclohexanecarbonyl chloride (5.40 g, 36.8 mmol) was added dropwise. The mixture was allowed to warm to 0 °C over 1 h and stirred at 0 °C for 1.5 h. Saturated NH₄Cl was added, and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic phases were washed with brine and dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:5 to 1:1 EtOAc:Hex to give **16** (4.48 g, 67%) as a pale yellow solid. Mp 64–65 °C. ¹H NMR δ 7.20–7.38 (m, 4H), 4.75 (bs, 1H), 2.57–2.68 (m, 1H), 2.48 (s, 3H), 1.10–1.80 (m, 10H). ¹³C NMR (CDCl₃/*d*₄-MeOH) δ 201.9, 140.5, 128.5, 127.7, 126.9, 126.0, 116.5, 29.0, 28.5, 25.3, 25.0, 15.2. MS *m/z* 274 (MH⁺), 291 (MNH₄⁺).

Anal. calcd (C₁₆H₁₉NOS): C, 70.29; H, 7.01; N, 5.12. Found: C, 70.41; H, 7.08; N, 4.90.

5.8.4. 2-[5-Amino-3-cyclohexyl-4-(4-methylthiophenyl)pyrazolyl]ethan-1-ol (17**).** A mixture of **16** (2.89 g, 10.6 mmol) and 2-hydroxyethylhydrazine (3.63 g, 47.6 mmol) in glacial AcOH (12 mL) was heated at 100 °C for 1 h. The residue after evaporation of the solvent was chromatographed on silica gel eluted with 1:10 MeOH:CH₂Cl₂ to give **17** (2.25 g, 64%) as a white solid. Mp 108–110 °C. ¹H NMR δ 7.16–7.40 (m, 4H), 3.95–4.15 (m, 4H), 3.75 (bs, 2H), 2.51–2.62 (m, 1H), 2.52 (s, 3H), 2.10 (bs, 1H), 1.15–1.95 (m, 10H). ¹³C NMR δ 149.0, 137.5, 130.9, 125.4, 124.5, 122.0, 98.4, 57.0, 44.0, 31.1, 27.6, 21.5, 20.9, 10.7. MS *m/z* 332 (MH⁺). Anal. calcd (C₁₈H₂₅N₃OS): C, 65.22; H, 7.60; N, 12.68. Found: 64.82; H, 7.50; N, 12.47.

5.8.5. 2-[5-Amino-3-cyclohexyl-4-(4-methylthiophenyl)pyrazolyl]ethyl methylsulfonate (18**).** To a stirred solution of **17** (1.32 g, 3.98 mmol) and triethylamine (0.83 mL, 0.67 g, 5.97 mmol) in CH₂Cl₂ (20 mL) at 0 °C under nitrogen, was added dropwise methanesulfonyl chloride (0.46 g, 0.31 mL, 3.98 mmol). The mixture was stirred at 0 °C for 10 min. Water was added, and the layers were separated. The organic phase was washed with water and dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:1 EtOAc:Hex to give **18** (1.04 g, 64%) as a colorless oil. ¹H NMR δ 7.31 (d, *J*=8.2 Hz, 2H), 7.16 (d, *J*=8.1 Hz, 2H), 4.60 (t, *J*=4.9 Hz, 2H), 4.31 (t, *J*=4.9 Hz, 2H), 3.63 (bs, 2H), 2.84 (s, 3H), 2.45–2.65 (m, 1H), 2.50 (s, 3H), 1.15–1.85 (m, 10H). ¹³C NMR δ 155.6, 143.1, 136.9, 130.7, 130.2, 127.6, 104.9, 69.6, 46.9, 37.4, 36.8, 33.4, 27.1, 26.5, 16.4. MS *m/z* 410 (MH⁺).

5.8.6. 1-(2-Cyclohexylimidazolidino[1,2-*d*]pyrazol-3-yl)-4-methylthiobenzene (19**).** Potassium carbonate (1.01 g, 7.33 mmol) was added to a solution of **18** (1.0 g, 2.44 mmol) in DMF (30 mL). The resultant mixture was stirred at room temperature for 1 h and at 60 °C for 16 h. The solid was filtered and the solvent was evaporated. Ethyl acetate was added, and the organic phase washed with water and dried over Na₂SO₄. The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:1 EtOAc:Hex to 0.1:1:1 MeOH:EtOAc:Hex to give **19** (0.34 g, 44%) as a pale brown solid. Mp 128–130 °C. ¹H NMR δ 7.20–7.35 (m, 4H), 4.12–4.25 (m, 2H), 3.90–4.05 (m, 2H), 3.70 (bs, 1H), 2.65–2.80 (m, 1H), 2.50 (s, 3H), 1.48–2.00 (m, 7H), 1.20–1.43 (m, 3H). ¹³C NMR δ 160.3, 150.9, 134.9, 131.2, 128.0, 127.5, 98.3, 49.2, 46.2, 37.3, 33.2, 26.9, 26.3, 16.3. MS *m/z* 314 (MH⁺). Anal. calcd (C₁₈H₂₃N₃S·1/4 mol H₂O): C, 67.99; H, 7.45; N, 13.22. Found: C, 68.27; H, 7.19; N, 13.07.

5.8.7. 1-(2-Cyclohexylimidazolidino[1,2-*d*]pyrazol-3-yl)-4-(methylsulfonyl)benzene (20**).** To a solution of **19** (100 mg, 0.32 mmol) in MeOH (3 mL) was added dropwise a solution of Oxone[®] (294 mg, 0.47 mmol) in water (0.6 mL) at 0 °C. The white suspension was stirred at 0 °C for 2 h. The solid was filtered and washed with CH₂Cl₂.

The filtrate was diluted with CH_2Cl_2 , and the layers were separated. The organic phase was washed with water and dried over Na_2SO_4 . The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 0.1:1:1 MeOH/EtOAc/Hex to give **20** (60 mg, 54%) as a white foam. Mp 57°C . ^1H NMR δ 7.84 (d, $J=8.3$ Hz, 2H), 7.47 (d, $J=8.3$ Hz, 2H), 4.32 (bs, 1H), 4.16 (t, $J=7.3$ Hz, 2H), 4.00 (t, $J=7.3$ Hz, 2H), 3.05 (s, 3H), 2.78 (tt, $J=3.1$ Hz and 11.8 Hz, 1H), 1.45–2.00 (m, 7H), 1.15–1.42 (m, 3H). ^{13}C NMR δ 154.8, 146.6, 135.2, 130.8, 122.6, 121.9, 92.1, 43.9, 40.8, 39.4, 32.2, 27.7, 21.5, 20.9. MS m/z 346 (MH^+). Anal. calcd ($\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}_2\text{S}\cdot 1/4$ mol H_2O): C, 61.77; H, 6.77; N, 12.00. Found: C, 61.70; H, 6.81; N, 11.81.

5.8.8. 4-Acetyl-2-cyclohexyl-3-[4-(methylsulfonyl)phenyl]-imidazolidino[1,2-*d*]pyrazole (21**).** To a solution of **20** (70 mg, 0.2 mmol) and DMAP (24.7 mg, 0.2 mmol) in CH_2Cl_2 (1 mL) was added dropwise acetic anhydride (38 μL , 41.4 mg, 0.2 mmol). The reaction mixture was stirred at room temperature for 24 h. The residue after evaporation of the solvent was dissolved in EtOAc, washed with 0.1 N HCl, water, dried over Na_2SO_4 , filtered and evaporated. The crude material was recrystallized from CH_2Cl_2 /EtOAc/Hex to give **21** (28 mg, 36%) as a white solid. Mp 198 – 199°C . ^1H NMR ($\text{DMSO}-d_6$) δ 7.80–8.04 (m, 2H), 7.29–7.52 (m, 2H), 4.48–4.62 (bs, 2H), 4.22–4.48 (bs, 2H), 3.11 (s, 3H), 2.28–2.48 (m, 1H), 1.91–2.28 (m, 1H), 1.40–1.87 (m, 9H), 1.08–1.37 (m, 3H). ^{13}C NMR ($\text{DMSO}-d_6$ at 373 K) δ 166.2, 159.5, 142.3, 140.3, 139.3, 131.8, 126.2, 102.4, 51.3, 45.2, 44.4, 36.9, 33.1, 26.5, 26.2, 22.7. MS m/z 388 (MH^+), 405 (MNH_4^+). Anal. calcd ($\text{C}_{20}\text{H}_{25}\text{N}_3\text{O}_3\text{S}$): C, 61.99; H, 6.50; N, 10.84. Found: C, 61.76; H, 6.22; N, 10.68.

5.8.9. 1-(6-Cyclohexyl-1-methylimidazolidino[1,2-*d*]pyrazol-7-yl)-4-(methylsulfonyl) benzene (22**).** A mixture of **20** (25 mg, 0.07 mmol), methyl iodide (4.5 μL , 10.3 mg, 0.07 mol) and K_2CO_3 (10 mg, 0.07 mmol) in DMF (0.4 mL) was stirred at room temperature for 7 days. The solvent was evaporated. The residue was chromatographed using preparative layer chromatography eluted with 1:1 EtOAc:Hex to give **22** (10.2 mg, 39%). Mp 138 – 140°C . ^1H NMR δ 7.93 (d, $J=8.4$ Hz, 2H), 7.45 (d, $J=8.4$ Hz, 2H), 4.16 (t, $J=7.4$ Hz, 2H), 3.73 (t, $J=7.3$ Hz, 2H), 3.10 (s, 3H), 2.57 (s, 3H), 2.41–2.57 (m, 1H), 1.15–1.90 (m, 10H). MS m/z 360 (MH^+).

5.9. *tert*-Butyl 2-{2-cyclohexyl-3-[4-(methylsulfonyl)phenyl]-imidazolidino[1,2-*d*]pyrazol-4-yl}acetate (24**)**

5.9.1. *tert*-Butyl 2-[2-cyclohexyl-3-(4-methylthiophenyl)-imidazolidino[1,2-*d*]pyrazol-4-yl]acetate (23**).** Compound **19** (0.22 g, 0.7 mmol) was dissolved in DMF (5 mL) and K_2CO_3 (0.19 g, 1.4 mmol) added followed by *tert*-butylbromoacetate (0.16 mL, 0.21 g, 1.1 mmol). The resulting solution was stirred at room temperature for 5 days, diluted with a large volume of EtOAc, washed with water, dried over Na_2SO_4 , filtered and evaporated. The residue was chromatographed on silica gel eluted with 1:1 EtOAc: CH_2Cl_2 to give **23** (0.24 g, 80%) as an

oil. ^1H NMR δ 7.21–7.27 (m, 2H), 7.12–7.21 (m, 2H), 4.19 (t, $J=7.4$ Hz, 2H), 3.91 (t, $J=8.4$ Hz, 2H), 3.57 (s, 2H), 2.51 (s, 3H), 2.42–2.64 (m, 1H), 1.42–1.95 (m, 7H), 1.39 (s, 9H), 1.12–1.32 (m, 3H). ^{13}C NMR δ 168.7, 160.8, 150.6, 136.0, 130.4, 129.9, 126.7, 97.9, 81.8, 55.4, 51.3, 45.8, 36.8, 33.2, 28.1, 26.8, 26.2, 16.0. MS m/z 428 (MH^+).

5.9.2. *tert*-Butyl 2-{2-cyclohexyl-3-[4-(methylsulfonyl)phenyl]imidazolidino[1,2-*d*]pyrazol-4-yl}acetate (24**).** To a solution of **23** (70 mg, 0.16 mmol) in MeOH (1.5 mL) was added dropwise a solution of Oxone[®] (150 mg, 0.25 mmol) in water (0.4 mL) at 0°C . The white suspension was stirred at 0°C for 6 h. The solid was filtered and washed with CH_2Cl_2 . The filtrate was diluted with CH_2Cl_2 and the layers were separated. The organic phase was washed with water, 5% NaHCO_3 , dried over Na_2SO_4 and filtered. The residue after evaporation of the solvent was chromatographed on silica gel eluted with 1:1 EtOAc: CH_2Cl_2 to give **24** (68 mg, 90%) as a white foam. Mp 56 – 58°C . ^1H NMR δ 7.91 (d, $J=8.3$ Hz, 2H), 7.42 (d, $J=8.3$ Hz, 2H), 4.22 (t, $J=7.5$ Hz, 2H), 3.95 (t, $J=7.4$ Hz, 2H), 3.56 (s, 2H), 3.10 (s, 3H), 2.42–2.62 (m, 1H), 1.50–1.95 (m, 7H), 1.36 (s, 9H), 1.10–1.30 (m, 3H). ^{13}C NMR δ 168.5, 160.5, 151.1, 139.6, 137.7, 130.0, 127.6, 97.1, 82.2, 55.7, 51.4, 45.9, 44.7, 36.9, 33.2, 28.1, 26.8, 26.2. MS m/z 460 (MH^+).

5.9.3. 2-{6-Cyclohexyl-7-[4-(methylsulfonyl)phenyl]-imidazolidino[1,2-*d*]pyrazolyl}acetic acid (25**).** To a solution of **24** (0.14 g, 0.3 mmol) in CH_2Cl_2 (1 mL) was added dropwise TFA (1 mL) at room temperature. The mixture was stirred at room temperature for 3 h. The solvent was evaporated. The residue was chromatographed on silica gel eluted with 0.1:1:1 MeOH:EtOAc:Hex to 2:8 MeOH: CH_2Cl_2 to give **25** (84 mg, 69%) as an off-white solid. Mp 83°C . ^1H NMR δ 7.93 (d, $J=8.1$ Hz, 2H), 7.44 (d, $J=8.2$ Hz, 2H), 4.24 (t, $J=7.5$ Hz, 2H), 3.98 (t, $J=7.7$ Hz, 2H), 3.71 (s, 2H), 3.10 (s, 3H), 2.47–2.57 (m, 1H), 1.67–1.82 (m, 4H), 1.40–1.60 (m, 2H), 1.10–1.32 (m, 4H). ^{13}C NMR δ 160.6, 151.3, 152.0, 138.1, 130.2, 127.8, 127.5, 97.4, 55.7, 50.6, 46.0, 44.7, 36.8, 33.0, 26.7, 26.1. MS m/z 404 (MH^+). LCMS (100%).

5.10. 1-(6-Cyclohexyl-2,2-dimethyl(3H-pyrazolo[5,1-*b*]1,3-oxazolidin-7-yl))-4-(methylsulfonyl)benzene (28**)**

5.10.1. 3-Cyclohexyl-1-(2-hydroxy-2-methylpropyl)-4-(4-methylthiophenyl)pyrazol-5-ol (26**).** A mixture of **3a** (0.25 g, 0.82 mmol) and 1-hydrazino-2-methyl-2-propanol³⁰ (0.38 g, 3.7 mmol) in glacial AcOH (3 mL) was heated at 95°C for 5 h. The solvent was evaporated. The residue was recrystallized from CHCl_3 /Hex to give **26** (0.2 g, 68%) as a white solid. MS m/z 361 (MH^+).

5.10.2. 1-(6-Cyclohexyl-2,2-dimethyl(3H-pyrazolo[5,1-*b*]1,3-oxazolidin-7-yl))-4-methylthiobenzene (27**).** A solution of **26** (0.16 g, 0.44 mmol) in neat phosphoric acid (1 mL) was heated at 70°C for 6 h. The reaction mixture was diluted with CH_2Cl_2 , and cooled to 0°C . Saturated NaHCO_3 was added, and the layers were separated. The aqueous layer was extracted with CH_2Cl_2 , the combined

organic phase was washed with saturated NaHCO_3 and dried over Na_2SO_4 . The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 1:1 EtOAc:Hex to give **27** (50 mg, 33%) as an oil. ^1H NMR δ 7.15–7.32 (m, 4H), 4.03 (s, 2H), 2.70–2.88 (m, 1H), 2.49 (s, 3H), 1.65 (s, 6H), 1.22–1.95 (m, 10H). ^{13}C NMR δ 160.3, 155.6, 134.9, 130.0, 127.8, 127.5, 94.6, 76.7, 57.3, 37.8, 32.9, 27.8, 26.9, 26.4, 16.5. MS m/z 343 (MH^+).

5.10.3. 1-(6-Cyclohexyl-2,2-dimethyl(3H-pyrazolo[5,1-b]1,3-oxazolidin-7-yl))-4-(methylsulfonyl)benzene (28). To a solution of **27** (30 mg, 0.09 mmol) in MeOH (1.1 mL) was added dropwise a solution of Oxone[®] (0.11 g, 0.18 mmol) in water (0.3 mL). The white suspension was stirred at room temperature for 1 h. The solid was filtered, and washed with CH_2Cl_2 . The filtrate was diluted with CH_2Cl_2 , and the layers were separated. The organic phase was washed with water and then dried over Na_2SO_4 . The residue after filtration and evaporation of the solvent was chromatographed on silica gel eluted with 0.1:1:1 MeOH:EtOAc:Hex to give **28** (18 mg, 55%) as a white solid. Mp 210 °C with dec. ^1H NMR δ 7.91 (d, $J=8.6$ Hz, 2H), 7.58 (d, $J=8.6$ Hz, 2H), 4.06 (s, 2H), 3.06 (s, 3H), 2.73–2.81 (m, 1H), 1.69 (s, 6H), 1.10–2.05 (m, 10H). MS m/z 375 (MH^+). LCMS (97.6%).

Acknowledgements

The authors wish to thank Dr. Radha Iyengar for helpful comments and suggestions.

References and notes

- Skoutakis, V. A.; Carter, C. A.; Micklee, T. R.; Smith, V. H.; Arkin, C. R.; Allissantos, J.; Petty, D. A. *Drug Intell. Clin. Pharm.* **1988**, *3*, 850.
- Lombardino, G. *Non Steroidal Anti-inflammatory Drugs*; John Wiley & Sons: New York, 1985.
- Dannhardt, G.; Kiefer, W. *Eur. J. Med. Chem.* **2001**, *36*, 109.
- Carter, J. S. *Exp. Opin. Ther. Pat* **2000**, *10*, 1011.
- Talley, J. J. *Prog. Med. Chem.* **1999**, *36*, 201.
- Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. *Proc. Natl. Acad. Sci. U.S.A.* **1991**, *88*, 2692.
- Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. *J. Biol. Chem.* **1991**, *266*, 12866.
- Chan, C. C.; Boyce, S.; Brideau, C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.; Ford-Hutchinson, A. W.; Forrest, M. J.; Gauthier, J. Y.; Gordon, R.; Gresser, M.; Guay, J.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Patrick, D.; Percival, M. D.; Perrier, H.; Prasit, P.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Visco, D.; Wang, Z.; Webb, J.; Wong, E.; Xu, L. J.; Young, R. N.; Zamboni, R.; Riendeau, D. *J. Pharmacol. Exp. Therap.* **1999**, *290*, 551.
- Hinz, B.; Brune, K. *J. Pharm. Exp. Therap.* **2002**, *300*, 367.
- DeWitt, D. L. *Mol. Pharmacol.* **1999**, *55*, 625.
- Mitchell, J. A.; Akarasereenont, P.; Thiemermann, C.; Flower, R. J.; Vane, J. R. *Proc. Natl. Acad. Sci. U.S.A.* **1993**, *90*, 11693.
- Penning, T. D.; Tally, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Doctor, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Coghburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. *J. Med. Chem.* **1997**, *40*, 1347.
- Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 1773.
- Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. *J. Med. Chem.* **2000**, *43*, 775.
- Meyer-Kirchdrath, J.; Schror, K. *Curr. Med. Chem.* **2000**, *7*, 1121.
- Catella-Lawson, F.; Crofford, L. J. *Am. J. Med.* **2001**, *110*, 28 S.
- Mukherjee, D.; Nissen, S. E.; Topol, E. J. *JAMA* **2001**, *286*, 954.
- Wolfe, M. M.; Lichtenstein, D. R.; Singh, G. N. *Engl. J. Med.* **1999**, *340*, 1888.
- de Gaetano, G.; Donati, M. B.; Cerletti, C. *Trends Pharm. Sci.* **2003**, *24*, 245.
- Beswick, P.; Campbell, I.; Naylor, A. PCT Appl. WO 96/31509, Oct. 10, 1996.
- Beswick, P.; Campbell, I.; Mathews, N.; Naylor, A. PCT Appl. WO 99/12930, March 18, 1999.
- Cossy, J.; Belotti, D. *Tetrahedron* **1999**, *55*, 5145.
- Laufer, S. A.; Augustin, J.; Dannhardt, G.; Kiefer, W. *J. Med. Chem.* **1994**, *37*, 1894.
- Kirschning, A.; Ries, M.; Domann, S.; Martin, W.; Albrecht, W.; Arnold, P.; Laufer, S. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 903.
- Dannhardt, G.; Steindl, L.; Lehr, M. US Patent 5,260,451, Nov. 9, 1993.
- Isakson, P. C.; Anderson, G. D.; Gregory, S. A. US Patent 6,136,839, Oct. 24, 2000.
- Laufer, S.; Striegel, H. G.; Dannhardt, G. US Patent 5,939,415, Aug. 17, 1999.
- (a) Kolasa, T.; Patel, M. V. US Patent 6,472,416 B1, Oct. 29, 2002 (b) Kolasa, T.; Patel, M. V. PCT Int. Appl., WO 01/016138, March 8, 2001.
- Gever, G. J. *Am. Chem. Soc.* **1954**, *76*, 1283.
- Potekhin, A. A.; Barkova, T. F. *J. Org. Chem. USSR* **1973**, 1209.
- Young, J. M.; Panah, S.; Satchawatcharaphong, C.; Cheung, P. S. *Inflamm. Res.* **1996**, *45*, 246.
- Glaser, K.; Sung, M. L.; O'Neill, K.; Belfast, M.; Hartman, D.; Carlson, R.; Kreft, A.; Kubrak, D.; Hsiao, C. L.; Weichman, B. *Eur. J. Pharmacol.* **1995**, *281*, 107.